menu
    • menu
    [{"orgOrder":0,"company":"PeptiDream","sponsor":"Fujitsu","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Fujitsu","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Fujitsu"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Peptide-drug Conjugates","moa":"TfR1","graph1":"Neurology","graph2":"Discovery","graph3":"PeptiDream","amount2":3.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":3.5,"dosageForm":"","sponsorNew":"PeptiDream \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Takeda"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Peptide-siRNA Conjugates","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"PeptiDream \/ Alnylam","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Alnylam"},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Peptide-radioisotope Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ RayzeBio","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ RayzeBio"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"PeptiDream \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Eli Lilly"},{"orgOrder":0,"company":"PeptiDream","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.1000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ MSD"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Not Applicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Amolyt Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AZP-3813","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PeptiDream \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"PeptiDream \/ PeptiDream"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Protein Degrader Drug","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.75,"dosageForm":"","sponsorNew":"PeptiDream \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Astellas Pharma"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Peptide-radioisotope Drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Genentech"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.8900000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.8900000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Not Applicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PD-29875","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PeptiDream \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PeptiDream

    Menu

    PeptiDream

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PeptiDream Reveals Oral Myostatin Inhibitor Prevents Lean Mass Loss with Semaglutide

                            Details : PeptiDream has discovered a series of potent macrocyclic and bridged-macrocyclic peptide inhibitors of myostatin, which are being evaluated for the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            December 12, 2024

                            Lead Product(s) : Undisclosed,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PD-29875

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PeptiDream Announces Radiopharmaceutical Program for Gastric Cancer Diagnosis, Treatment

                            Details : PD-29875 is a novel first-in-class highly-selective macrocyclic peptide-radioisotope conjugate against Claudin 18.2 expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 12, 2024

                            Lead Product(s) : PD-29875

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,890.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

                            Details : PeptiDream will use its peptide discovery platform to identify and optimize novel macrocyclic peptides against targets selected by Novartis, potentially for radionuclide conjugation.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : $180.0 million

                            April 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,890.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-radioisotope Drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of N...

                            Details : Under the collaboration, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to discover, optimize, and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to ...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 19, 2023

                            Lead Product(s) : Peptide-radioisotope Drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein Degrader Drug

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : $749.9 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Pro...

                            Details : The collaboration aims to discover novel protein degraders by leveraging PeptiDream's PDPS (Peptide Discovery Platform System) technology, for two targets and Astellas will have the option to select up to three additional targets to be included in the co...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : $21.2 million

                            July 25, 2023

                            Lead Product(s) : Protein Degrader Drug

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : $749.9 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-3813

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : Amolyt Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GH...

                            Details : AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.

                            Product Name : AZP-3813

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : AZP-3813

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : Amolyt Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate

                            Details : Candidate was discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization and sustained tumor specific uptake and anti-tumor efficacy in pre-clini...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : $2,100.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel P...

                            Details : Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 27, 2022

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : $2,100.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,235.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PeptiDream Announces New Research and Collaboration Agreement with Lilly for the Discovery of Novel Peptide Dr...

                            Details : Under the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest for the discovery and development of novel p...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 26, 2022

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,235.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            PeptiDream

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-radioisotope Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : RayzeBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics

                            Details : Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs. RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI program...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            August 09, 2022

                            Lead Product(s) : Peptide-radioisotope Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : RayzeBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth